

Financial news for CYCCP dated on 2019-07-22: Cyclacel Pharmaceuticals Announces First Patient Treated In Phase 1/2 Study Of Sapacitabine And Venetoclax In Relapsed Or Refractory AML Or MDS Patients

Financial news for CYCCP dated on 2019-04-01: Cyclacel Pharma Give an Updated From Phase 1 Data

Financial news for CYCCP dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for CYCCP dated on 2018-09-24: Stocks Which Set New 52-Week Low Friday, September 21st

Financial news for CYCCP dated on 2018-04-16: Cyclacel Reports Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

Financial news for CYCCP dated on 2015-09-17: Cyclacel Announces Presentation of Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias, Lymphomas

Financial news for CYCCP dated on 2015-07-02: Cyclacel Announces First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease,

Financial news for CYCCP dated on 2015-06-29: Cyclacel & ManRos Therapeutics Reports Licensing, Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis

Financial news for CYCCP dated on 2015-04-20: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Different Anti-Cancer Compounds

Financial news for CYCCP dated on 2015-03-04: Cyclacel Pharmaceuticals Prices 10M Share Offering at \$1.00/Share

Financial news for CYCCP dated on 2014-12-16: Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis

Financial news for CYCCP dated on 2014-10-09: Cyclacel Announces Data Safety Monitoring Board Recommends Continuation of Seamless Phase 3 Trial of Sapacitabine in AML

Financial news for CYCCP dated on 2014-09-18: Cyclacel Pharma Reports CYC065 CDK Inhibitor Shows Therapeutic Potential in Acute Leukemias with MLL Rearrangements

Financial news for CYCCP dated on 2014-04-09: Cyclacel Pharmaceuticals, Inc. Announces Closing of \$10 Million Underwritten Offering

Financial news for CYCCP dated on 2013-12-09: Cyclacel Reports Positive Phase 2 Data of Sapacitabine for MDS at ASH

Financial news for CYCCP dated on 2013-11-25: Cyclacel Pharma Announces Data Safety Monitoring Board Recommends Continuation of SEAMLESS Study of Sapacitabine in AML

Financial news for CYCCP dated on 2013-08-12: Cyclacel's Seliciclib to be Evaluated for RA

Financial news for CYCCP dated on 2013-05-15: Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for CYCCP dated on 2013-04-04: Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene, Dismissal of All Claims in Their Patent Litigation

Financial news for CYCCP dated on 2013-04-04: Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene for \$5.5M

Financial news for CYCCP dated on 2013-01-07: Cyclacel Comments on Key Business Objectives for 2013

Financial news for CYCCP dated on 2012-12-17: Aspire Capital Fund to Purchase Up to \$20M of Cyclacel Common Stock for \$6.29/Share

Financial news for CYCCP dated on 2012-12-04: Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th

Financial news for CYCCP dated on 2012-11-05: Cyclacel Receives \$1.9M Grant

Financial news for CYCCP dated on 2012-10-15: Data Shows Cyclacel's Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS

Financial news for CYCCP dated on 2012-09-20: Morning Market Movers

Financial news for CYCCP dated on 2012-09-13: Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

Financial news for CYCCP dated on 2012-08-24: Cyclacel Announces Reverse 1-for-7 Stock Split

Financial news for CYCCP dated on 2011-12-07: Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients

Financial news for CYCCP dated on 2011-07-07: Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock and Warrants

Financial news for CYCCP dated on 2011-07-01: Cyclacel Pharmaceuticals Announces Pricing of Underwritten Offering at \$1.36/Share

Financial news for CYCCP dated on 2011-01-26: Morning Market Movers (BLTI, CYDE, MSHL, STRZ)

Financial news for CYCCP dated on 2010-10-07: Cyclacel Completes Previously Announced Private Placement

Financial news for CYCCP dated on 2010-10-05: Cyclacel Announces Private Placement Financing for Up to \$22.1M